You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
Dose-ranging safety and efficacy studies to advance novel mechanism-of-action small molecule leads to treat obesity-linked type 2 diabetesSBC: RIDGELINE THERAPEUTICS LLC Topic: NIDDK
ABSTRACTA staggeringof US adults are obeseSince obesity greatly dysregulates glucose homeostasisalmost all obese individuals suffer from TypediabetesT Dor prediabetesThese diseasesand accompanying comorbid chronic health complicationsare largely responsible for burgeoning US healthcare costsUnfortunatelylife style modification programstypically the first line treatment for obesity linked T Drarely ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: HEMEX HEALTH INC Topic: NIDDK
PROJECT SUMMARY Diabetes is one of the most important health issues in the worldIt is a disease that disproportionately affects low and middle income countriesNot only is diabetes a major cause of morbidity and mortalityit can devastate the finances of families and strain countriesfinancial resourcesKey components for addressing this healthcare crises include early diagnosis as well as ongoing mon ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: Innovative BioChips LLC Topic: NIA
PROJECT SUMMARY Developing an Automated Yeast Dissection System for Aging ResearchAging is the single greatest risk factor for diseases that are principal causes of mortalityThe objectives of aging research are to discover key genes and pathways related to aging that may eventually contribute to retardation of aging and a delay in the onset of age associated diseasesThe budding yeast Saccharomyces ...STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: South Plains Biotechnology, Inc Topic: 350
Project Summary Abstract Statement of the problemOnly three pharmacotherapeutic treatments for Alcohol Use DisorderAUDare FDA approved and none are widely usedandltof AUD patientsor show a strong effect to reduce riskyor dependence based drinking in the long termandltsee sustained decreased drinking outcomesUnfortunatelyapproximatelyof the population suffers from AUD and overof all medical morbidi ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: Meridian Biotech, LLC Topic: 101
The over arching goal of this Phase I SBIR proposal is to begin to optimize and implement standard reference diets for the ZebrafishDanio rerioan animal model of critical importance to the understanding of human health and development of vertebrate organismsA key problem in the industry is that standardized diets or feed management strategies have not been developed for Danio rerioThese diets are ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
Dose-ranging safety and efficacy studies to advance novel mechanism-of-action drug candidates to reverse age-related muscle degenerationSBC: RIDGELINE THERAPEUTICS LLC Topic: NIA
In the USthe number of individuals agedand older will increase byover the next decadeConcurrentlyMedicare costs are expected to double to treat chronic diseases that will plague this increasing number of older adultsOne of the most wide spread chronic diseases that affects older adults is sarcopeniawhich is observed inof adults overyears of age andof adults overyears of ageThis disease is characte ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: BERTEC CORP Topic: NIA
Falls are a significant source of early morbidity and mortality in the aging populationyet the neurologicalsensoryand motor changes that lead to increased fall risk often escape early identification and interventionVital signs are commonly used in clinical settings to assess the cardiovascular systemblood pressureheart rateimmune systembody temperatureand the respiratory systemrespiratory rateto e ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.SBC: ARCHER PHARMACEUTICALS, INC. Topic: NIA
Pathological hallmarks of Alzheimerandapos s diseaseADinclude extracellular deposits of Apeptidesintraneuronal aggregates of abnormally phosphorylated tau protein and neuroinflammationMost proposed AD disease modifying therapies have focused on strategies that reduce brain Aamyloid or tau pathological accumulationHoweversuch approaches have been unsuccessful in late stage AD clinical trials and ma ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: NeoView, Inc. Topic: NICHD
PROJECT SUMMARY In this Phase I Small Business Technology TransferSTTRprojecta team of researchers at Cincinnati Childrenandapos s Hospital Medical CenterCCHMCwill work with the engineering team at NeoViewIncto design and build novel body coil and incubator prototypes for aTesla Neonatal Intensive Care UnitNICUMRI systemThese components will play a central role in NeoViewandapos s neonatal MRI pro ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: CERSCI THERAPEUTICS INCORPORATED Topic: 102
Project SummaryAbstract The World Health Organization ranks migraine as therd most prevalent disease worldwide andth most disablingth most in womenmaking it the most common neurological disorderOne of the primary reasons for the disabling nature of migraine is the poor efficacy of currently available therapeuticsLess thanof patients achieve complete relief with acute agents such as triptans and on ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health